Abstract Number: 2831 • 2013 ACR/ARHP Annual Meeting
Increased Risk Of Autism Spectrum Disorders In Children Born To Women With SLE: Preliminary Data From The O S L E R Cohort
Background/Purpose: Recent experimental data suggest in utero exposure to maternal antibodies and cytokines as important risk factors for autism spectrum disorders (ASD). Interestingly, women with…Abstract Number: 2832 • 2013 ACR/ARHP Annual Meeting
The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus
Background/Purpose: Neonatal Lupus (NLE) results from passive transfer of anti-Ro and/or anti-La antibodies to the fetus during gestation. It has been suggested that prenatal exposure…Abstract Number: 2833 • 2013 ACR/ARHP Annual Meeting
Increased Cardiac Septal Defects In Children Born To Women With Systemic Lupus Erythematosus: Results From The O S L E R Study
Background/Purpose: Cardiac septal defects, which include atrial septal defects (ASD) and ventricular septal defects (VSD), are the most frequent congenital heart anomalies in the general…Abstract Number: 2834 • 2013 ACR/ARHP Annual Meeting
Maternal data Analysis Of The French Registry Of 205 Cases Of Immune Congenital Heart Block (neonatal lupus)
Background/Purpose: Congenital heart block (CHB) occurs in 1 to 2 % of pregnancies exposed to anti-SSA antibodies. Few data are available regarding the risk of…Abstract Number: 2835 • 2013 ACR/ARHP Annual Meeting
Safety Of Gardasil® Vaccine In Systemic Lupus Erythematosus
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…Abstract Number: 2836 • 2013 ACR/ARHP Annual Meeting
Development of a Health Index in Patients With Ankylosing Spondylitis (ASAS HI) – Final Result of a Global Initiative Based On the International Classification of Functioning, Disability and Health (ICF) Guided By Assesment of Spondyloarthritis International Society (ASAS)
Background/Purpose: The impact of ankylosing spondylitis (AS) on a patient’s life can be considerable. Patients suffer from pain, stiffness and fatigue, are limited in their…Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…Abstract Number: 2798 • 2013 ACR/ARHP Annual Meeting
Bone Marrow In Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion Of Somatically Mutated, Activated Naive Cells Comprised Of Substantial Clonal Expansions
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease where autoreactive antibodies are produced as a result of abnormal B cell activation and broken self-tolerance. This…Abstract Number: 2799 • 2013 ACR/ARHP Annual Meeting
Identification Of IL-10 Producing Plasma Cells In Human and Its Deficiency In Systemic Lupus Erythematosus Patients
Background/Purpose: Regulatory B cells are active participants in down-regulating inflammation and autoimmunity, through the production of IL-10. Despite intensive studies in mice, there is only…Abstract Number: 2800 • 2013 ACR/ARHP Annual Meeting
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study – A Twelve Month Placebo Controlled, Randomized, Double Blind Study
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL. It inhibits osteoclast-induced bone resorption by preventing the binding of…Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…Abstract Number: 2802 • 2013 ACR/ARHP Annual Meeting
A Treat-To-Target Strategy With Methotrexate and Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression In Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study
Background/Purpose: The aim was to investigate if a treat-to-target strategy with methotrexate and intra-articular glucocorticoid suppressed synovitis and osteitis, and halted structural damage progression in…Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…Abstract Number: 2804 • 2013 ACR/ARHP Annual Meeting
Radiological Outcome Of Joints With MRI Detected Subclinical Inflammation In Early Arthritis Patients
Background/Purpose: Extremity-MRI is becoming important in Rheumatoid Arthritis (RA) research as it is a sensitive tool to assess inflammation. Inflammation is measured by three features:…